AEON Biopharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
AEON$0.18-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value amounts)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · September 30, · · December 31, · | |||||||
| · 2025 · 2024 · | |||||||
| · · (Unaudited) · · · | |||||||
| ASSETS · · · | |||||||
| Current assets: · · · | |||||||
| Cash and cash equivalents | | $5,927 | | $13 | | ||
| Prepaid expenses and other current assets | | 1,485 | | 1,577 | | ||
| Total current assets | | 7,412 | | 1,590 | | ||
| Property and equipment, net | | 181 | | 235 | | ||
| Operating lease right-of-use asset | | 1,112 | | 1,288 | | ||
| Other assets | | 29 | | 29 | | ||
| Total assets | | $8,734 | | $3,142 | | ||
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | | | ||||
| Current liabilities: | | | | ||||
| Accounts payable | | $2,525 | | $5,910 | | ||
| Accrued clinical trials expenses | | 1,524 | | 3,571 | | ||
| Accrued compensation | | 1,547 | | 1,068 | | ||
| Other accrued expenses | | 2,632 | | 3,600 | | ||
| Total current liabilities | | 8,228 | | 14,149 | | ||
| Convertible notes at fair value, including related party amount of $17,051 and $11,689, at September 30, 2025 and December 31, 2024, respectively | | 17,051 | | 11,689 | | ||
| Operating lease liability | | 957 | | 1,145 | | ||
| Warrant liability | | | 2,338 | | | 1,187 | |
| Contingent consideration liability | | | 32 | | | 3,541 | |
| Total liabilities | | 28,606 | | 31,711 | | ||
| Commitments and contingencies (Note 6) | | | | ||||
| Stockholders’ Deficit: | | | | | |||
| Class A common stock, $0.0001 par value; 1,040,000,000 and 500,000,000 shares authorized at September 30, 2025 and December 31, 2024, and 11,643,786 and 555,511 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | | 9 | | 4 | | ||
| Additional paid-in capital | | 413,801 | | 403,024 | | ||
| Accumulated deficit | | (433,682) | | (431,597) | | ||
| Total stockholders' deficit | | (19,872) | | (28,569) | | ||
| Total liabilities and stockholders' deficit | | $8,734 | | $3,142 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.